A Single Dose Study of MK-8690 in Healthy Japanese Participants

A Single-Dose Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-8690 in Healthy Japanese Participants

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2051250077

Enrollment

Registered

2025-07-29

Start date

2025-09-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

MK-8690 240 mg, 480 mg, or placebo will be administered as a single subcutaneous injection, or MK-8690 800 mg or placebo will be administered as a single intravenous injection.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy male participants and female participants of nonchildbearing potential between the ages of 18 and 60 years

Exclusion criteria

Exclusion criteria: Has a history of clinically significant abnormalities or diseases

Design outcomes

Primary

Measure	Time frame
Adverse events	—

Secondary

Measure	Time frame
Pharmacokineticks	—

Contacts

Public ContactMSDJRCT inquiry mailbox

MSD K.K.

msdjrct@msd.com+81-3-6272-1957

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026